Your Health. Your Family. Your Choice.
|History of Changes from the VAERS Wayback Machine|
|Vaccination / Manufacturer||Lot / Dose||Site / Route|
|COVID19: COVID19 (COVID19 (PFIZER-BIONTECH)) / PFIZER/BIONTECH||- / 1||- / -|
Administered by: Other Purchased by: ??
Symptoms: Thrombophlebitis superficial
Life Threatening? No
Birth Defect? No
Permanent Disability? No
Office Visit (V2.0)? No
ER or Office Visit (V1.0)? No
ER or ED Visit (V2.0)? No
Diagnostic Lab Data:
CDC 'Split Type': DEPFIZER INC2021647969
Write-up: superficial vein thrombosis; This is a spontaneous report from a non-contactable consumer (patient). This is a report based on information received by Pfizer from Biontech Se (manufacturer control number 60777), license party for BNT162B2. A male patient of an unspecified age received the first dose of bnt162b2 (COMIRNATY), via an unspecified route of administration on 18May2021 (Batch/Lot number was not reported) as single dose for covid-19 immunisation. The patient medical history was not reported. The patient''s concomitant medications were not reported. The patient experienced superficial vein thrombosis on 01Jun2021. As reported: 2 weeks ago patient received BNT vaccination after that, superficial venetrombosis. Side effect: doctor reported 2 weeks ago exactly. The gentleman was vaccinated 2 weeks ago with the 1st dose of the BioNTech vaccine. He has developed superficial vein thrombosis. He still has it at the moment. It is not serious, he was treated by the doctor. But the doctor did not know if he could get the 2nd dose. That''s why he called us. The doctor has probably already reported the side effect. The outcome was not recovered No follow-up attempts are possible, information about lot/batch number cannot be obtained.
Copyright © 2021 National Vaccine Information Center. All rights reserved.
21525 Ridgetop Circle, Suite 100, Sterling, VA 20166